Endocr Connect. 2026 Apr 1:EC-25-0756. doi: 10.1530/EC-25-0756. Online ahead of print.
ABSTRACT
OBJECTIVE: X-linked hypophosphatemia (XLH) is the most common congenital phosphate disorder affecting individuals throughout the lifespan. We investigated the skeletal burden, the cardiovascular involvement, the diagnostic performance and therapeutic management in a cohort of Italian adults with XLH.
DESIGN: cross-sectional study involving 15 Italian tertiary centers.
METHODS: retrospective study.
RESULTS: 170 adults (110 females, 60 males), aged 44.6±14.6 (19-83) years, were identified. 1) Skeletal deformities were detected in 87.1% of individuals, fractures/pseudofractures in 44.7%, osteophytosis in 65.4% and enthesopathies in 57.6%. Dental disease affected 72.4% of individuals. The skeletal burden was heavier in males than females. 2) Hypertension occurred in 14.7% of individuals and was associated with elevated plasma intact FGF23 levels; dyslipidemia, diabetes and cerebrovascular events occurred in very few individuals. 3) FGF23 levels were measured in 30.0% of individuals; they were >30 pg/mL (nv 23-95) in nearly all individuals but overtly elevated in 58.8%. Genetic analysis has been performed in 86.5% of the cohort, PHEX mutations were identified in 95.2% of the individuals without evidence of genotype/phenotype correlation. 4) 44.2% of individuals were on conventional therapy, 32.5% were on burosumab, and 23.3% were untreated. Individuals having received diagnosis in the adulthood (n=14) were neither medically nor surgically treated during their childhood.
CONCLUSIONS: the burden of XLH disease in adulthood is determined by skeletal manifestations and dental disease and may be more severe in males. Additionally, cardiometabolic impairment may not be common. The disease burden impacts most of individuals, beyond those presenting the criteria for burosumab reimbursement.
PMID:41921026 | DOI:10.1530/EC-25-0756